EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill

HIV Medicine · 2026

DOI: 10.1111/hiv.70128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Tali Faggiano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, University of California, San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART).

Methods

This is a retrospective cohort study at a single‐centre primary care HIV clinic. Included were adults who received at least one injection of LAI CAB/RPV between April 2021 and March 2024. Characteristics were compared between those that continued LAI CAB/RPV and those that discontinued treatment during the study period. HIV viral load (VL) outcomes were evaluated in those that returned to oral ART and included the most recent VL in the range of 1–24 weeks, 24–48 weeks and the most recently documented VL through September 2024.

Results

A total of 92 and 346 patients were included in the discontinuation and continuation cohorts, respectively. Being male sex assigned at birth and having psychiatric disease was associated with continuing LAI CAB/RPV, whereas having active substance use and being on a multi‐class regimen prior to initiation of LAI CAB/RPV was associated with discontinuation. In those with VL data after resuming oral ART, the percentage of those with HIV VL

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRilpivirinePyridonesAnti-HIV AgentsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedViral LoadAdministration, OralTreatment OutcomeInjectionsDiketopiperazines

Stichwörter der Autor:innen

antiretroviral therapycabotegravirdiscontinuationrilpivirineviral suppression

Substanzen

RilpivirinecabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Pharmacy Department, University of California, San Diego, San Diego, California, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, California, USA.
  • Owen Clinic, University of California, San Diego, San Diego, California, USA.

Zitieren

APA

Faggiano, T., Yin, J., Patel, N., Karim, A., Abulhosn, K., Bamford, L., & Hill, L. (2026). Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy. HIV Medicine. https://doi.org/10.1111/hiv.70128

Vancouver

Faggiano T, Yin J, Patel N, Karim A, Abulhosn K, Bamford L, et al. Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy. HIV Medicine. 2026. doi:10.1111/hiv.70128

BibTeX
@article{Faggiano2026,
  author = {Faggiano, Tali and Yin, Jeffrey and Patel, Nimish and Karim, Afsana and Abulhosn, Kari and Bamford, Laura and Hill, Lucas},
  title = {Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70128}
}
Kostenlos starten →